Tag: Lixiana

European Trial Data

European trial data ‘reinforce’ safety profile and efficacy of Lixiana

Daiichi Sankyo Europe has announced outcomes from an observational study in mainly caucasian atrial fibrillation (AF) patients being treated with the anti-coagulation drug edoxaban...
Cardiac Rhythm news for specialists

First patient enrolled in Daiichi Sankyo’s ELIMINATE-AF edoxaban study

The first patient has been enrolled into Daiichi Sankyo’s ELIMINATE-AF study. The multinational, randomised phase 3b study will explore the safety and efficacy of...
Cardiac Rhythm news for specialists

Daiichi Sankyo begins ENTRUST-AF PCI study of once-daily edoxaban

The first patient has been enrolled into Daiichi Sankyo’s ENTRUST-AF PCI study. The multinational, randomised phase 3b study will evaluate a treatment regimen based...
Cardiac Rhythm news for specialists

Health Canada approves edoxaban for two indications

Health Canada has approved edoxaban (Lixiana, Servier Canada) for the prevention of stroke and for systemic embolic events in patients with non-valvular atrial fibrillation,...